Recent News

• 04.02.2025 - Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.11.2025 - Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
• 03.04.2025 - Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.04.2025 - TD Cowen 45th Annual Health Care Conference
• 02.27.2025 - Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema
• 02.25.2025 - Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference
• 02.20.2025 - Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress
• 02.11.2025 - Oppenheimer 35th Annual Healthcare Life Sciences Conference

Recent Filings

• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2025 - 8-K Current report
• 03.11.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.11.2025 - EX-99.1 EX-99.1
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors